{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:16:09Z","timestamp":1791353769843,"version":"4.3.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.canlet.2014.01.033","type":"journal-article","created":{"date-parts":[[2014,2,4]],"date-time":"2014-02-04T19:17:18Z","timestamp":1391541438000},"page":"22-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: Treatment-free remission as a new goal in chronic myeloid leukemia"],"prefix":"10.1016","volume":"347","author":[{"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Alimena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2014.01.033_b0005","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"Hughes","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2014.01.033_b0010","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"European Leukemianet. Chronic myeloid leukemia: an update of concepts and management recommendations od European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2014.01.033_b0015","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2014.01.033_b0020","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.01.033_b0025","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","article-title":"Standardized definitions of molecular response in chronic myeloid leukemia","volume":"26","author":"Cross","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2014.01.033_b0030","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: chronic myeloid leukemia. Version 4.2013. February 2013. Available from: <www.nccn.org\/professionals\/physician qls\/pdf\/cml-pdf>."},{"key":"10.1016\/j.canlet.2014.01.033_b0035","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"suppl. 1","key":"10.1016\/j.canlet.2014.01.033_b0040","first-page":"152","article-title":"Deciding to continue or discontinue therapy in chronic myeloid leukemia","volume":"7","author":"Mahon","year":"2013","journal-title":"Hematol. Educ."},{"key":"10.1016\/j.canlet.2014.01.033_b0045","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","article-title":"Discontinuation of imatinib therapy after achieving a molecular response","volume":"104","author":"Cortes","year":"2004","journal-title":"Blood"},{"issue":"suppl. 1","key":"10.1016\/j.canlet.2014.01.033_b0050","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.leukres.2003.10.017","article-title":"Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission","volume":"28","author":"Mauro","year":"2004","journal-title":"Leuk. Res."},{"key":"10.1016\/j.canlet.2014.01.033_b0055","first-page":"979","article-title":"Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation","volume":"90","author":"Merante","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2014.01.033_b0060","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.01.033_b0065","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Intergroupe Fran\u00e7ais des Leuc\u00e9mies My\u00e9lo\u00efdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2014.01.033_b0070","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1182\/blood.V118.21.603.603","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular response: update results of the STIM study","volume":"118","author":"Mahon","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.01.033_b0075","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.01.033_b0080","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3324\/haematol.2011.056853","article-title":"Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia","volume":"97","author":"Takahashi","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2014.01.033_b0085","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.leukres.2012.02.011","article-title":"Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response","volume":"36","author":"Yhim","year":"2012","journal-title":"Leuk. Res."},{"key":"10.1016\/j.canlet.2014.01.033_b0090","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1182\/blood.V120.21.2788.2788","article-title":"Detailed investigation on characteristics of Japanese patients with chronic phase CML who achieved a durable CMR after discontinuation of imatinib-an updated result of the Keio STIM study","volume":"120","author":"Matsuki","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.01.033_b0095","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/ajh.23427","article-title":"Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib","volume":"88","author":"Lee","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.canlet.2014.01.033_b0100","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1016\/j.ejca.2013.06.018","article-title":"Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian cooperative trial for haemato-oncology (HOVON)","volume":"49","author":"Thielen","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2014.01.033_b0105","first-page":"10","article-title":"Patient-driven discontinuation of tyrosine kinase inhibitors-single institution experience","author":"Benjamini","year":"2013","journal-title":"Leuk. Lymphoma"},{"issue":"suppl. 1","key":"10.1016\/j.canlet.2014.01.033_b0110","first-page":"194","article-title":"Loss of major molecular response is accurate for restarting imatinib after imatinib discontinuation in CP-CML patients with long lasting CMR: importance of fluctuating values of MRD and interferon","volume":"97","author":"Rousselot","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2014.01.033_b0115","doi-asserted-by":"crossref","first-page":"5138","DOI":"10.1182\/blood-2013-01-480194","article-title":"Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia","volume":"121","author":"Russo","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.01.033_b0120","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.3324\/haematol.2011.048165","article-title":"Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features","volume":"96","author":"Ross","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2014.01.033_b0125","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1182\/blood.V120.21.916.916","article-title":"Discontinuation of second generation (2G) tyrosine kinase inhibitors (TKI) in chronic phase (CP)-chronic myeloid leukemia (CML) patients with stable undetectable BCR-ABL transcripts","volume":"120","author":"Rea","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.01.033_b0130","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","article-title":"Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia","volume":"28","author":"Burchert","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2014.01.033_b0135","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/blood.V120.21.1684.1684","article-title":"Sustained molecular response with maintenance dose of interferon alfa after imatinib discontinuation in patients with chronic myeloid leukemia","volume":"120","author":"Usuki","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.01.033_b0140","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.3324\/haematol.2013.090381","article-title":"What challenges remain in chronic myeloid leukemia research?","volume":"98","author":"Carella","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2014.01.033_b0145","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1373\/clinchem.2007.085472","article-title":"Development of an integrated assay for detection of BCR-ABL RNA","volume":"53","author":"Winn-Deen","year":"2007","journal-title":"Clin. Chem."},{"key":"10.1016\/j.canlet.2014.01.033_b0150","doi-asserted-by":"crossref","first-page":"896","DOI":"10.3109\/10428194.2011.555569","article-title":"Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay","volume":"52","author":"Goh","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.canlet.2014.01.033_b0155","doi-asserted-by":"crossref","first-page":"6812","DOI":"10.1158\/1078-0432.CCR-11-0396","article-title":"BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment","volume":"17","author":"Stein","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2014.01.033_b0160","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1182\/blood-2012-07-441956","article-title":"Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia","volume":"121","author":"Horn","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.01.033_b0165","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","article-title":"Dynamics of chronic myeloid leukemia","volume":"435","author":"Michor","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2014.01.033_b0170","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.01.033_b0175","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1002\/cncr.27506","article-title":"Evaluation of residual CD34(+)Ph(+) progenitors cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy","volume":"118","author":"Defina","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2014.01.033_b0180","doi-asserted-by":"crossref","first-page":"713","DOI":"10.18632\/oncotarget.333","article-title":"Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy","volume":"2","author":"Chomel","year":"2011","journal-title":"Oncotarget"},{"issue":"suppl. 1","key":"10.1016\/j.canlet.2014.01.033_b0185","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2012.0184","article-title":"Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure","volume":"10","author":"Cortes","year":"2012","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.canlet.2014.01.033_b0190","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nchembio.775","article-title":"BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia","volume":"8","author":"Hantschel","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.canlet.2014.01.033_b0195","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2174\/187152010790909326","article-title":"Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia","volume":"10","author":"Chen","year":"2010","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.canlet.2014.01.033_b0200","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccr.2010.03.011","article-title":"Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate","volume":"17","author":"Zhang","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2014.01.033_b0205","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccr.2011.12.020","article-title":"Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib","volume":"21","author":"Li","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2014.01.033_b0210","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1084\/jem.20110304","article-title":"BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia","volume":"208","author":"Hurtz","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2014.01.033_b0215","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","article-title":"Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo","volume":"12","author":"Zhao","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2014.01.033_b0220","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/leu.2008.262","article-title":"Beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL induced chronic myeloid leukemia","volume":"23","author":"Hu","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2014.01.033_b0225","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.stem.2012.02.017","article-title":"Genetic and pharmacologic inhibition of beta-catenin targets imatinib-resistant leukemia stem cells in CML","volume":"10","author":"Heidel","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.canlet.2014.01.033_b0230","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.stem.2012.03.006","article-title":"Targeting beta-catenin in CML: leukemia stem cells beware!","volume":"10","author":"Kleppe","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.canlet.2014.01.033_b0235","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1182\/blood-2012-02-412890","article-title":"Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors trough N-cadherin and Wnt-beta-catenin signalling","volume":"121","author":"Zhang","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.01.033_b0240","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.canlet.2011.08.002","article-title":"Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65\u2014a novel Wnt\/beta catenin signalling inhibitor","volume":"312","author":"Nagao","year":"2011","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2014.01.033_b0245","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07737","article-title":"Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukemia","volume":"458","author":"Zhao","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2014.01.033_b0250","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.4161\/cc.9.17.12945","article-title":"Hedgehog pathway activation in chronic myeloid leukemia","volume":"9","author":"Jagani","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1016\/j.canlet.2014.01.033_b0255","first-page":"30:8","article-title":"Activation of the Hedgehog pathway in chronic myelogenous leukemia patients","volume":"16","author":"Long","year":"2011","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2014.01.033_b0260","doi-asserted-by":"crossref","first-page":"6884","DOI":"10.1158\/0008-5472.CAN-08-1101","article-title":"BCR\/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair","volume":"68","author":"Cramer","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2014.01.033_b0265","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.stem.2012.12.011","article-title":"A pan BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition","volume":"12","author":"Goff","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.canlet.2014.01.033_b0270","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1600-0609.2010.01497.x","article-title":"WT1 peptide vaccine induces reduction in minimal residual disease in an imatinib-treated CML patient","volume":"85","author":"Oji","year":"2012","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.canlet.2014.01.033_b0275","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1182\/blood-2010-08-300376","article-title":"High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells","volume":"117","author":"Quintarelli","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.01.033_b0280","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/cas.12216","article-title":"Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib","volume":"104","author":"Mizoguchi","year":"2013","journal-title":"Cancer Sci."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383514000901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383514000901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T01:59:00Z","timestamp":1597456740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383514000901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0304383514000901"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2014.01.033","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: Treatment-free remission as a new goal in chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2014.01.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}